Your browser doesn't support javascript.
loading
Apatinib plus etoposide in pretreated patients with advanced triple-negative breast cancer: a phase II trial.
Cao, Mengru; Lu, Hailing; Yan, Shi; Pang, Hui; Sun, Lichun; Li, Chunhong; Chen, Xuesong; Liu, Wei; Hu, Jing; Huang, Jian; Xing, Ying; Zhang, Ningzhi; Chen, Yingqi; He, Ting; Zhao, Danni; Sun, Yuanyuan; Zhao, Lin; Liu, Xiaomeng; Cai, Li.
Afiliación
  • Cao M; The Fourth Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
  • Lu H; The First Ward of the Oncology Department, The First Affilliated Hospital of Harbin Medical University, Harbin, China.
  • Yan S; The Fourth Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
  • Pang H; The Fourth Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
  • Sun L; The Fourth Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
  • Li C; The Fourth Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
  • Chen X; The Fourth Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
  • Liu W; The Fourth Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
  • Hu J; The Fourth Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
  • Huang J; The Fourth Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
  • Xing Y; The Fourth Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
  • Zhang N; The Fourth Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
  • Chen Y; The Fourth Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
  • He T; The Fourth Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
  • Zhao D; The Fourth Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
  • Sun Y; The Fourth Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
  • Zhao L; The Fourth Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
  • Liu X; The Fourth Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
  • Cai L; The Fourth Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China. caiwenxin76@163.com.
BMC Cancer ; 23(1): 463, 2023 May 19.
Article en En | MEDLINE | ID: mdl-37208633
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama Triple Negativas / Hipertensión / Antineoplásicos Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Revista: BMC Cancer Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article País de afiliación: China
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama Triple Negativas / Hipertensión / Antineoplásicos Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Revista: BMC Cancer Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article País de afiliación: China